Last, knockdown of the two genes, PLA2G4A and DOCK1, caused significant reductions in cellular growth, invasion and tumorigenic capability; therefore, the two genes might become therapeutic targets for AML patients. This evidence concerns the gene DOCK1 and acute myeloid leukemia.